What is Cytrellis?
Based in Woburn, Massachusetts, Cytrellis operates at the intersection of advanced engineering and dermatology. The company has developed a novel class of aesthetic devices that utilize mechanical energy to remove sagging skin associated with aging. By offering a non-surgical alternative that avoids the risks of scarring and prolonged recovery times, Cytrellis is effectively disrupting the traditional cosmetic surgery market. Their technology is engineered to provide measurable, natural-looking results, catering to a growing demographic of patients seeking minimally invasive aesthetic solutions.
How much funding has Cytrellis raised?
Cytrellis has raised a total of $86M across 4 funding rounds:
Series A
$7.1M
Series B
$28.5M
Debt
$350K
Series C
$50M
Series A (2015): $7.1M with participation from ARCH Venture Partners
Series B (2018): $28.5M led by ARCH Ventures, Biomatics Capital, Partner Fund Management, and Merz Venture Initiative
Debt (2020): $350K supported by PPP
Series C (2021): $50M featuring PFM Health Sciences, Sands Capital, D1 Capital Partners, and ARCH Venture Partners
Key Investors in Cytrellis
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Biomatics Capital
Biomatics Capital is a for-profit venture firm focused on investing in transformative data-enabled innovations at the intersection of health care and technology, aiming to support superior therapeutics and diagnostics.
PFM Health Sciences
Founded in 2004, PFM Health Sciences is a leading healthcare investment advisor currently managing approximately $2 billion in public and private investments.
What's next for Cytrellis?
With the recent infusion of capital, Cytrellis is well-positioned to scale its commercial operations and expand its market footprint. The strategic focus will likely shift toward broader clinical adoption and the potential expansion of its product portfolio to address additional dermatological indications. As the company transitions from a development-heavy phase to a commercial scaling stage, the continued support from institutional investors will be critical in navigating the regulatory and competitive complexities of the global aesthetic market. Future milestones will likely center on increasing physician training programs and enhancing the accessibility of their proprietary technology to clinics worldwide.
See full Cytrellis company page
